Kanwal Raghav

Trials

Studies that name Kanwal Raghav as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:07 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07071961 · Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

  M.D. Anderson Cancer Center · recruiting · Colorectal Cancer, Regorafenib, High Risk Patients · principal investigator
• Ph2
  NCT05900648 · Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

  M.D. Anderson Cancer Center · withdrawn · Colorectal Cancer, Colon Cancer, Rectum Cancer · principal investigator
• Ph2
  NCT05024968 · Sintilimab in Cancer of Unknown Primary

  M.D. Anderson Cancer Center · completed · Cancer of Unknown Primary Site · principal investigator
• Ph2
  NCT03844620 · Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

  M.D. Anderson Cancer Center · active not recruiting · Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8 · principal investigator
• Ph2
  NCT03365882 · S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  SWOG Cancer Research Network · completed · Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 17:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• A technological approach for performance status assessment in advanced cancer patients
  R01CA243554 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2024 · $546,557 awarded in 2024
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• SWOG Network Group Operations Center of the NCTN
  U10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026
  Named on NCT03365882